Meloxicam Tablet
Product Images NDC 71610-872

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Meloxicam (NDC 71610-872). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0872 30)

MELOXICAM 15 mg tablets label for oral use, containing 30 tablets. The label includes storage instructions to keep at controlled room temperature (68-77 degrees F) in a tight light-resistant container. Manufactured by PD-Rx Pharmaceuticals in Oklahoma City and repackaged by Aphena Pharma Solutions in Cookeville, TN. The label displays the NDC number 71610-872-30.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Mg1 (Mg1)

Text panel containing warnings related to NSAIDs use, specifically advising not to take NSAIDs before or after coronary artery bypass graft (CABG) surgery and cautioning against use after a recent heart attack due to increased risk of another heart attack.*

FDA Label Image

Mg2 (Mg2)

A text panel listing risk factors for increased likelihood of ulcers or bleeding associated with NSAID use. It includes medical conditions, medications such as corticosteroids and anticoagulants, lifestyle factors, age, health status, and other contributing elements relevant to the risk assessment.*

FDA Label Image

Mg3 (Mg3)

Text panel containing usage instructions for MELOXICAM 15 mg oral tablets, emphasizing taking the medication exactly as prescribed, at the lowest effective dose, and for the shortest necessary duration. The panel outlines general guidelines for treatment adherence without specific dosing details.*

FDA Label Image

Mg4 (Mg4)

A partial Drug Facts or warning text panel listing symptoms including shortness of breath, chest pain, weakness in one side of the body, slurred speech, and swelling of the face or throat. The text appears to be part of safety information related to the medication.*

FDA Label Image

Mg5 (Mg5)

A text panel listing possible side effects of the drug Meloxicam, including symptoms such as nausea, diarrhea, yellowing of skin or eyes, vomiting blood, unusual weight gain, skin rash, and swelling of limbs. The content is structured as bullet points describing various adverse reactions.*

FDA Label Image

Structural (Structural Formula)

Chemical structure of Meloxicam, showing its molecular components including a thiazole ring, sulfonamide group, and hydroxyl group characteristic of this anti-inflammatory drug molecule.*

FDA Label Image

Table 1a (Table 1a)

A table presenting adverse events occurring in 2% or more of patients taking Meloxicam or comparator drugs over a 12-week osteoarthritis clinical trial. Columns compare placebo, Meloxicam 7.5 mg daily, Meloxicam 15 mg daily, and Diclofenac 100 mg daily across categories such as gastrointestinal, body as a whole, nervous system, respiratory, and skin events.*

FDA Label Image

Table 1b (Table 1b)

Data table displaying adverse events occurring in 2% or more of Meloxicam patients from two 12-week rheumatoid arthritis placebo-controlled trials. It compares incidence percentages for placebo, Meloxicam 7.5 mg daily, and Meloxicam 15 mg daily groups across various disorders including gastrointestinal, general disorders, infections, musculoskeletal, nervous system, and skin disorders.*

FDA Label Image

Table 2.1 (Table 2.1)

A data table listing adverse reactions by system organ class for the drug Meloxicam. The table includes categories such as Body as a Whole, Cardiovascular, Central and Peripheral Nervous System, Gastrointestinal, Heart Rate and Rhythm, Hematologic, Liver and Biliary System, Metabolic and Nutritional, Psychiatric, Respiratory, Skin and Appendages, Special Senses, and Urinary System, with associated specific adverse events under each category.*

FDA Label Image

Table 2 (Table 2)

A data table presenting percentages of adverse events occurring in 2% or more of Meloxicam patients during 4 to 6 week and 6 month active-controlled osteoarthritis trials. The table compares Meloxicam 7.5 mg daily and 15 mg daily dosages across categories such as gastrointestinal, body as a whole, central and peripheral nervous system, hematologic, musculoskeletal, psychiatric, respiratory, skin, and urinary.*

FDA Label Image

Table 3.1 (Table 3.1)

This text panel details drug interaction clinical impacts and recommended interventions for meloxicam when used with lithium, methotrexate, cyclosporine, NSAIDs, salicylates, and pemetrexed. It highlights increased risks such as lithium toxicity, methotrexate toxicity, cyclosporine nephrotoxicity, GI toxicity, and myelosuppression. Monitoring and dosage adjustments are advised during concomitant use.*

FDA Label Image

Table 3 (Table 3)

A data table listing clinically significant drug interactions with Meloxicam by drug categories including anticoagulants, aspirin, ACE inhibitors, beta-blockers, and diuretics. It details clinical impacts and recommended interventions for each interaction type in patients taking Meloxicam.*

FDA Label Image

Image Description (Table 4)

A data table presenting single dose and steady-state pharmacokinetic parameters for oral meloxicam in 7.5 mg and 15 mg doses. It includes metrics such as Cmax, tmax, half-life, clearance, and volume of distribution across different populations including healthy adults, elderly males and females, and patients with renal or hepatic insufficiency, with associated variability percentages.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.